$44.26
+0.67 (+1.54%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where VCEL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional · 2 observational · 2 with posted results
Held by 14 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, D. E. Shaw & Co., Inc., Point72 Asset Management, L.P., Balyasny Asset Management L.P., AQR CAPITAL MANAGEMENT LLC, +9 more) · FINRA short interest 8.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 9 sells · government filings 180d: 0 congress / 2 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the AnkleNCT06915233Change from Baseline to Week 104 in the FAOS Pain and Function (SRA) subscale scoresRandomized · Open-label · Treatment | Phase 3 | Recruiting | Biological: autologous cultured chondrocytes on porcine collagen membrane · Procedure: Bone Marrow Stimulation | Chondral Defect, Articular Cartilage Defect | 309 | Jul 2030 | ≤ 1,442 d | 2026-07-23 |
| A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the KneeNCT03588975Proportion of Participants Who Achieve ≥ 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Subscale ScoresRandomized · Open-label · Treatment | Phase 3 | Recruiting | Biological: MACI · Procedure: microfracture | Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee | 45 | Feb 2030 | ≤ 1,289 d | 2026-06-24 |
| An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)NCT01670981Average number of clinical events over 12 months post-treatment.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: ixmyelocel-T · Other: Placebo | Ischemic Dilated Cardiomyopathy (IDCM) | 114 | 2016-02-01actual | — | 2021-05-27 |
| Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the KneeNCT01251588results2017-04-27observationalChange From MACI00206 Baseline for the Participant's Knee Injury and Osteoarthritis Outcome (KOOS) Pain and Function (Sports and Recreational Activities) Scores. | — | Completed | Biological: autologous cultured chondrocytes on porcine collagen membrane · Procedure: Microfracture | Articular Cartilage Defects | 128 | Mar 2015actual | — | 2021-05-12 |
| An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)NCT01483898Amputation free survival (AFS) at 12 months post-injectionRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: Ixmyelocel-T · Other: Placebo | Critical Limb Ischemia | 41 | 2014-03-25actual | — | 2021-05-27 |
| Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)NCT00765518Safety will be assessed by: post-procedure assessments, physical exam, vital signs, laboratory tests, and adverse events including MACE (Major Adverse Cardiac Event) occurrences.Randomized · Open-label · Treatment | Phase 2 | Completed | Biological: Ixmyelocel-T · Other: Standard of Care | Dilated Cardiomyopathy | 40 | 2012-09-05actual | — | 2021-05-27 |
| Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the KneeNCT00719576results2017-12-14Change From Baseline to Week 104 for the Participant's Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain and Function (Sports and Recreational Activities) Scores.Randomized · Open-label · Treatment | Phase 3 | Completed | Biological: autologous cultured chondrocytes on porcine collagen membrane · Procedure: Microfracture | Articular Cartilage Defect | 144 | Mar 2012actual | — | 2021-05-12 |
| Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated CardiomyopathyNCT01020968Incidence of major adverse cardiac event (MACE) (MACE defined as: cardiac death, cardiac arrest, myocardial infarction, sustained ventricular arrhythmias, pulmonary edema, acute heart failure, unstable angina and major bleeding)Randomized · Open-label · Treatment | Phase 2 | Completed | Biological: Ixmyelocel-T · Other: Vehicle Control | Dilated Cardiomyopathy | 22 | 2012-01-11actual | — | 2021-05-27 |
| Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb IschemiaNCT00468000Safety of TRCs in patients with CLI(key safety parameters include vital signs, physical exams, laboratory results, assessment of aspiration and injection sites, adverse events, major amputations, wounds presence(size and grading using the Wagner scale)Randomized · Double-masked · Treatment | Phase 2 | Completed | Biological: Ixmyelocel-T, Placebo | Peripheral Arterial Disease | 86 | Mar 2011actual | — | 2020-05-20 |
| Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral HeadNCT00505219The progression of patients with UPenn Stage IIB or IIC disease to a more severe stage based on all available x-ray and MRI imaging. Patients who have a definitive procedure but do not have a valid assessment will be considered to have progressed.Randomized · Single-masked · Treatment | Phase 3 | Completed | Biological: Ixmyelocel-T · Other: Standard of Care Only | Osteonecrosis | 11 | Sep 2010actual | — | 2019-10-21 |
| The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry PatientsNCT00140634observationalPhysician assessment of effectiveness of autologous chondrocyte implantation | — | Completed | Biological: Carticel (autologous cultured chondrocyte) implantation | Articular Cartilage, Cartilage Diseases | 2,233 | Jan 2009actual | — | 2021-05-11 |
| Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine FusionNCT00797550The primary objective is to confirm that the TRC product, when used as a bone graft, is safe for use in posterolateral lumbar spinal fusion surgery, on the basis of defined radiographic evidence of bone fusion.Randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Study was terminated early for business reasons (not safety reasons). | Biological: Bone Repair Cells (BRCs) · Procedure: Autologous bone graft | Single Level Posterolateral Spinal Fusion | 2 | Aug 2006actual | — | 2021-05-11 |
| Study of the Treatment of Articular Repair (STAR)NCT00158613Mean change from baseline in the KOOSNon-randomized · Open-label · Treatment | Phase 4 | Completed | Biological: Carticel (autologous cultured chondrocyte) implantation | Articular Cartilage | 126 | Nov 2005actual | — | 2021-05-11 |
| Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.NCT00424567The primary endpoint will be the proportion of patients with demonstrated healing, including bone formation, at 12 months (or until completely healed) from surgery.Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Closed early for business reasons (not safety reasons) | Procedure: Fracture surgery · Drug: Cultured Bone Marrow Tissue | Fracture, Ununited, Pseudarthrosis | 36 | — | — | 2021-05-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19